HCPCS Level II code J9260 denotes a 50 mg injectable dose of methotrexate sodium, a systemic antineoplastic and immunosuppressant used across oncology and certain autoimmune indications. Nationally, this code is used to capture the drug product and supports billing for outpatient and infusion-based administrations where parenteral chemotherapy or disease-modifying therapy is provided. Accurate coding of J9260 matters for clinical documentation, drug-cost reporting, and payer reimbursement consistency.

Key national payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for methotrexate injection, typical sites of service where J9260 is reported, common billing modifiers used with injectable drugs, and the typical payer mix involved in outpatient chemotherapy and specialty drug claims.

The publication provides benchmarks and coding guidance context, clarifies what information is and is not available in the source data, and outlines areas where policy updates or payer-specific rules commonly affect claim adjudication for injectable chemotherapeutics like methotrexate. Data not available in the input is noted where applicable.